Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
Sponsor: Navitor Pharmaceuticals, Inc.
Listed as NCT03606395, this PHASE1 trial focuses on Treatment Resistant Depression and remains completed. Sponsored by Navitor Pharmaceuticals, Inc., it has been updated 8 times since 2018, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 3 earlier versions
-
Mar 2019 — Aug 2019 [monthly]
Recruiting PHASE1
-
Jan 2019 — Mar 2019 [monthly]
Recruiting PHASE1
-
Aug 2018 — Jan 2019 [monthly]
Recruiting PHASE1
First recorded
Jun 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Navitor Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .